Revenue: $83 million in 2024 on a pro forma basis. Cash Balance: Over $600 million, providing runway into 2027. Milestone Payments: $45 million from Sanofi and Roche for achieving technical goals.

Cash Position: Ended the quarter with $509 million in cash. Cash Burn: $118 million during Q1 2025, including cash operating expenses and capital expenditures. Cash Runway: Expected to extend into mid ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 26,086 calls trading, 1.1x expected, and implied vol increasing almost 32 points to 119.88%. 10/31 weekly 6 calls and Oct-25 5.5 ...